Rare Disease Phase 3 Deal Benchmarks — China (2026)

Median upfront of $153M with total deal values reaching $685M in China territory.

Median Upfront

$153M

Total Deal Value

$527M

Royalty Range

5.7%–10.2%

Territory Multiplier

0.12x

Understanding Rare Disease Deal Benchmarks at Phase 3

Phase 3 Rare Disease licensing deals in China territory command a median upfront payment of $153M, with values ranging from $92M at the low end to $208M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the rare disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $369M to $685M, with a median of $527M. Royalty rates for rare disease assets at this stage typically fall between 5.7% and 10.2% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The China territory applies a 0.12x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating china rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

PRO

See All Comparable Deals

View 0 comparable Rare Disease transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Phase 3 Rare Disease deals in China territory?

The median upfront payment for Phase 3 Rare Disease licensing deals in China territory is $153M, based on our analysis of comparable transactions. Values range from $92M for early-stage or less differentiated assets up to $208M for premium programs with strong clinical data or first-in-class mechanisms.

How does China territory affect Rare Disease deal value?

China rights carry a 0.12x multiplier relative to base deal economics. This means china rare disease deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Phase 3 Rare Disease licensing?

Royalty rates for Phase 3 rare disease assets typically range from 5.7% to 10.2% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$6M upfront

Rare Disease · Preclinical · China

$14M upfront

Rare Disease · Phase 1 · China

$45M upfront

Rare Disease · Phase 2 · China

$406M upfront

Rare Disease · Approved · China

$87M upfront

Oncology · Phase 3 · China

$62M upfront

Neurology/CNS · Phase 3 · China

$108M upfront

Immunology · Phase 3 · China

$148M upfront

Metabolic/Obesity · Phase 3 · China

Explore More

All Rare Disease Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Rare Disease · Phase 3

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Rare Disease Phase 3 Deal Benchmarks — China (2026). Retrieved from https://calculator.ambrosiaventures.co/data/rare-disease-phase-3-deals-china

HTML

<a href="https://calculator.ambrosiaventures.co/data/rare-disease-phase-3-deals-china">Rare Disease Phase 3 Deal Benchmarks — China (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$92M	$153M	$208M
Total Deal Value	$369M	$527M	$685M
Royalty Rate	5.7%	—	10.2%